Esseku Frederick, Joshi Anjali, Oyegbile Yemisi, Edowhorhu Grace, Gbadero Daniel, Adeyeye Moji
Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA, USA.
Antivir Ther. 2013;18(2):205-12. doi: 10.3851/imp2310.
This study aimed to test the hypothesis that the paediatric fixed-dose combination granule for reconstitution (comprising lamivudine/zidovudine/nevirapine 30/60/50 mg per 5 ml) as a test product is bioequivalent to the coadministered single entities of the referenced products. Fixed-dose combination anti-retroviral therapy provides adequate suppression of HIV-1 replication, provides barrier to the development of resistance, simplifies dosage regimen and improves adherence.
An open label, randomized, two-way crossover study was conducted on 24 health adults under fasted conditions, with a washout period of 14 days between treatments. A total of 15 blood samples were collected before dosing and up to 96 h post dosing. The drugs were extracted from plasma and anlaysed using a validated high performance liquid chromatography- ultraviolet method. Non- compartmental pharmacokinetic (PK) analysis was performed to obtain the PK parameters, maximum plasma concentration (C max), area under the curve of plasma concentration-time curves from the time zero to last measurable concentration (AUC0-t) and the area under the curve extrapolated to infinity (AUC 0-∞) ANOVA test was performed to determine the effect of model factors on the PK parameters. The two one-sided t-tests were performed on the log-transformed data to determine the 90% CL for the ratio of test to reference PK parameters.
The drugs were well tolerated and safe with minimal adverse events. The ANOVA test indicated the absence of any significant effects ( P>0.05) due to the model parameters. The 90% Cl for the geometric mean ratio of the test/reference for the Cmax, AUC0-t and the AUC0-∞ for lamivudine, zidovudine and nevirapine were within 80-125% bioequivalence limits.
This single dose randomized study found that the test and reference products met the criteria for bioequivalence in the fasting healthy adult volunteers.
本研究旨在验证以下假设:作为测试产品的小儿用复方固定剂量颗粒剂(每5毫升含拉米夫定/齐多夫定/奈韦拉平30/60/50毫克)与对照产品的联合使用单一组分具有生物等效性。固定剂量的抗逆转录病毒联合疗法可充分抑制HIV-1复制,防止耐药性产生,简化给药方案并提高依从性。
在24名健康成年人中进行了一项开放标签、随机、双向交叉研究,研究在禁食条件下进行,治疗之间的洗脱期为14天。给药前及给药后长达96小时共采集15份血样。从血浆中提取药物并使用经过验证的高效液相色谱-紫外法进行分析。进行非房室药代动力学(PK)分析以获得PK参数、最大血浆浓度(Cmax)、从时间零点至最后可测浓度的血浆浓度-时间曲线下面积(AUC0-t)以及外推至无穷大的曲线下面积(AUC0-∞)。进行方差分析(ANOVA)以确定模型因素对PK参数的影响。对对数转换后的数据进行两次单侧t检验,以确定测试与对照PK参数比值的90%置信区间(CL)。
药物耐受性良好且安全性高,不良事件极少。方差分析表明,模型参数未产生任何显著影响(P>0.05)。拉米夫定、齐多夫定和奈韦拉平的Cmax、AUC0-t和AUC0-∞的测试/对照几何平均比值的90%置信区间在生物等效性限度的80-125%之内。
这项单剂量随机研究发现,测试产品和对照产品在禁食的健康成年志愿者中符合生物等效性标准。